Skip to main content
SpringerLink
Log in

Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertension

  • Letter to the Editors
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Anderson JR, Nawarskas JJ (2010) Pharmacotherapeutic management of pulmonary arterial hypertension. Cardiol Rev 18(3):148–162

    Article  PubMed  Google Scholar 

  2. Jansa P, Becvar R, Ambroz D, Palecek T, Tomcik M, Skacelova S, Aschermann M, Linhart (2011) A Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. Clin Rheumatol (Epub ahead of print)

  3. Stringham R, Shah NR (2010) Pulmonary arterial hypertension: an update on diagnosis and treatment. Am Fam Phys 82(4):370–377

    Google Scholar 

  4. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon J, Steg PG, Tardif J-C, Tavazzi L, Tendera M, for the Heart Rate Working Group (2007) Resting heart rate in cardiovascular disease. J Am Coll Cardiol 50:823–830

    Article  PubMed  Google Scholar 

  5. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB et al (2006) Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 27(1):65–75

    Article  PubMed  Google Scholar 

  6. Flannery G, Gehrig-Mills R, Billah B, Krum H (2008) Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 101(6):865–869

    Article  PubMed  CAS  Google Scholar 

  7. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875–885

    Article  PubMed  CAS  Google Scholar 

  8. Werdan K, Ebelt H, Nuding S, Höpfner F, Hack G, Müller-Werdan U (2012) Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol (Epub ahead of print)

  9. Nuding S, Ebelt H, Hoke RS, Krummenerl A, Wienke A, Müller-Werdan U, Werdan K (2011) Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine: MODI (f)Y trial. Clin Res Cardiol 100(10):915–923

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, University of Foggia, “Ospedali Riuniti”OO.RR, viale L Pinto, 1, 71100, Foggia, Italy

    Michele Correale, Deodata Montrone, Matteo Di Biase & Natale Daniele Brunetti

Authors
  1. Michele Correale
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deodata Montrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matteo Di Biase
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Natale Daniele Brunetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michele Correale.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Correale, M., Montrone, D., Biase, M.D. et al. Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertension. Clin Res Cardiol 101, 593–594 (2012). https://doi.org/10.1007/s00392-012-0437-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-012-0437-1

Keywords

Search

Navigation